Managing Director, SPARC, Milken Institute Philanthropy
Cara Altimus, PhD is a managing director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at the Milken Institute, leading the science and health innovation portfolio. A PhD neuroscientist, Altimus advises individual philanthropists and foundations on the state of research for various areas including neurodegenerative disease and mental health, identifying opportunities where their capital can make the biggest impact.
Misophonia was named and described in the early 2000’s (Jastreboff and Jastreboff, 2001, 2002) and has since gained scientific recognition and clinical identification across a wide variety of disciplines (e.g., audiology, neuroscience, occupational therapy, psychiatry, and psychology). To the layperson, misophonia could be narrowly understood as a strong dislike of certain sounds, such as chewing. However, despite a common appreciation that misophonia is present in individuals when specific sensory input, such as a particular sound, leads to strong emotional and physical responses, researchers and clinicians have characterized the disorder differently (e.g., Jastreboff and Jastreboff, 2002; Edelstein et al., 2013; Schröder et al., 2013; Wu et al., 2014; Brout et al., 2018). Scientific research investigating misophonia has been conducted for fewer than 20 years and the literature on misophonia has only recently surpassed 100 peer-reviewed papers. During this early phase of research, misophonia has been defined by different criteria with variable methods used to diagnose and assess symptom severity. As a result of this fundamental lack of consensus regarding how misophonia is defined and evaluated, comparisons between study cohorts are not possible, measurement tools have not been well psychometrically validated, and the field cannot rigorously assess the efficacy of different treatment approaches.
Countries undergoing population aging today are facing a much different experience than their historical counterparts. One only needs to look at the countries in Asia to see how these trends are unfolding. Demographic aging is happening...
The Milken Institute Center for Strategic Philanthropy and the Ann Theodore Foundation have released a new request for proposals (RFP) focused on understanding the underlying biology of sarcoidosis. Applications are open through January 20...
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...
Even before the onset of the COVID-19 pandemic, the United States was confronted with a number of significant policy concerns. Today, working together to solve those challenges is more imperative than ever. The Milken Institute is committed...
Frontotemporal dementia (FTD) refers to a family of neurodegenerative conditions that cause changes in behavior, mood, executive function, language, memory, and motor function. As many as 30,000 people are living with FTD in the United...
The Ann Theodore Foundation Breakthrough Sarcoidosis Initiative (ATF-BSI) is now accepting applications for two-year research projects that seek to increase our foundational understanding of sarcoidosis through projects focused on the...
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public...
While some sounds can be annoying for most people, for a few, certain sounds like chewing, sniffling, or pen clicking can trigger an intense physical and emotional response. Those with this condition can experience increased heart rate...
This year’s report, Building a Resilient America: The New Consensus for Action, is part of The Milken Institute-Harris Poll Listening Project, now in its fifth year, which surveys socioeconomic, institutional, and political barriers to...